Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours
Open Access
- 1 May 1987
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 55 (5) , 509-512
- https://doi.org/10.1038/bjc.1987.103
Abstract
Recent biochemical and pharmacological findings concerning tamoxifen (TMX) have proven that both the unchanged drug and the main metabolites, N-desmethyltamoxifen (NDT) and 4-hydroxytamoxifen (4OHT) are biologically active. An HPLC method based on on-line post-column UV irradiation with fluorescence detection is described. Optimized conditions allowed complete and rapid separation of TMX 4OHT, NDT and two other recently reported metabolites, Y and Z. This method was applied to plasma and cytosol drug and metabolite analyses. In plasma, from the moment of initial drug administration until the steady state (after 1 month or more of continuous oral TMX treatment), the values of NDT to TMX ratios were completely reversed: 22 to 215 in mean %, P less than 0.01. The presence of metabolites Y and Z is significant. 4OHT, hardly detectable at the first dose, was measured at the steady state with high interpatient variability. It is hypothesized that metabolite evolution with time may be due to auto-induction of drug metabolism. In cytosols, which were all obtained during continuous TMX treatment, the ratios between TMX and metabolites were comparable to those observed in plasma, but with greater interpatient variability. Metabolite Y was not detectable in cytosols. This variability was not linked to the levels of cytosolic oestradiol receptors before initiation of treatment.Keywords
This publication has 24 references indexed in Scilit:
- Antiestrogen binding sites in human breast cancer biopsies. Measurement ligand-specificity and affinity, and correlation to estrogen and progesterone receptors.1985
- DIFFERENTIAL SENSITIVITY OF HUMAN-BREAST CANCER CELL-LINES TO THE GROWTH-INHIBITORY EFFECTS OF TAMOXIFEN1985
- Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flareEuropean Journal of Cancer and Clinical Oncology, 1984
- ANTIESTROGEN BINDING IN ANTIESTROGEN GROWTH-RESISTANT ESTROGEN-RESPONSIVE CLONAL VARIANTS OF MCF-7 HUMAN-BREAST CANCER-CELLS1984
- Comparative binding affinities of tamoxifen, 4‐hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: Correlation with blood levels in patients with metastatic breast cancerBiopharmaceutics & Drug Disposition, 1981
- Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancerCancer Chemotherapy and Pharmacology, 1980
- The binding of tamoxifen to human mammary carcinoma cytosolPublished by Elsevier ,1980
- Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules.1980
- Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.1980
- Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1980